A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Study of MK-8228 (Letermovir) vs. Valganciclovir for Prevention of CMV Disease in Adult Kidney Transplant Recipients
Sponsor: Merck Sharpe & Dohme Corp.
Enrolling: Male and Female Patients
IRB Number: AAAR7454
U.S. Govt. ID: NCT03443869
Contact: Marcus Pereira, MD, MPH: 212-305-0914 / mp2323@cumc.columbia.edu
Additional Study Information: The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and is the current standard of care for CMV disease prevention in kidney transplant recipients. The study will last for approximately one year (52 weeks). Study treatment will start within seven days post-transplant and continue through 28 weeks. In total, subjects will be monitored for CMV disease for approximately a year after transplant.
This study is closed
Marcus Pereira, MD, MPH
Do You Qualify?
Have you been told you tested positive for cytomegalovirus (CMV)? Yes No
Will you receive a kidney transplant soon? Yes No
Are you a multi-organ transplant recipient? Yes No
Are you on dialysis? Yes No
Are you pregnant or are you expecting to donate eggs or sperm? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Marcus Pereira, MD, MPH